Healthy volunteers will receive each of the three injections (the two anesthetics and the placebo) in separate study periods, with the order chosen at random and neither the participants nor the staff knowing which injection is given at any time. After each injection, a small device will apply electrical stimulation to create a temporary area of increased pain sensitivity called hyperalgesia, and participants will rate the pain they feel. Additional tests will use a cuff that inflates around the arm to measure the pressure at which pain is first felt and the pressure that can be tolerated, known as cuff-pressure algometry. Throughout the study, blood pressure, heart rate, any side effects and adverse events will be recorded, and each participation period lasts only a few days.

The purpose of the study is to evaluate how the body processes the medication and to monitor its safety. Researchers will observe how the drug is absorbed into the bloodstream, how it moves throughout the body, and how it is eventually eliminated. Additionally, the study will track how the body reacts to the treatment to ensure it is safe for use in this age group.

The purpose of the study is to evaluate the bioavailability, which refers to the amount of a drug that enters the bloodstream and becomes available to produce an effect, and to see how eating food influences this process. During the trial, participants will receive a single dose of the medication under different conditions. This includes periods where they have not eaten, known as a fasted state, and periods after consuming a meal, known as a fed state. By comparing these different scenarios, researchers can determine if the liquid form works similarly to the capsule form and how food intake affects the medication’s performance.

During the study, participants who are hospitalized for rheumatological conditions will receive both forms of the medication at different times. The study will measure how the medication moves through the body and how well it is absorbed when given as a tablet compared to when it is given as an injection. This information will help determine the most effective way to give the medication to future patients.

The research will analyze several aspects of how the medication works in the body, including how long it takes to reach its highest level in the blood, how long it stays in the body, and how much of the medication becomes available for use. This information will help doctors better understand the differences between the tablet and injectable forms of Nefopam and potentially improve pain treatment for patients with rheumatological conditions.

Participants in the study will receive either the lidocaine spray or a placebo before the catheter is inserted. The main goal is to measure the level of pain felt by participants using a simple pain scale, known as the Numerical Rating Scale (NRS), which allows individuals to rate their pain on a scale from 0 to 10. The study will specifically look at pain levels in two areas: the back of the hand and the forearm. By comparing the pain levels between those who receive the lidocaine spray and those who receive the placebo, researchers hope to determine the effectiveness of the spray in reducing pain.

The trial will be conducted in a controlled and randomized manner, meaning participants will be randomly assigned to receive either the lidocaine spray or the placebo, and neither the participants nor the researchers will know which treatment is being given until the study is completed. This approach helps ensure that the results are unbiased and reliable. The study is expected to provide valuable insights into pain management during routine medical procedures, potentially improving the comfort and experience for patients undergoing similar treatments in the future.

The main purpose of the study is to evaluate how the peripheral nervous system, which is the part of the nervous system outside the brain and spinal cord, responds to the medication. This is done using a method called Quantitative Sensory Testing (QST), which measures how the body senses things like touch, temperature, and pain. The study will look at changes in these sensory measurements after the medication is given.

Participants in the study will receive two different doses of Halneuron and will undergo sensory testing to see how their responses change. The study will also compare the effects of the two doses and monitor any side effects that may occur. The goal is to gather information on how tetrodotoxin affects sensory perception and to ensure its safety for future use in managing pain.

The purpose of this research is to determine if the bovine-derived chondroitin sulfate works as effectively as the marine-derived version for treating pain and reduced function caused by knee osteoarthritis. The study examines how well both medications work in reducing knee pain and improving the ability to perform daily activities.

Participants in this study will take the assigned medication for 24 weeks (6 months). During this time, they will need to record their pain levels and ability to perform everyday activities. After the treatment period ends, there will be a 12-week follow-up period to continue monitoring the effects of the medication. Throughout the study, participants may be allowed to take paracetamol as a pain reliever if needed.

The purpose of the study is to compare the effects of these two medications on patients experiencing severe acute pain in emergency departments. Specifically, the study will look at the occurrence of any psychodysleptic effects, which are unusual mental or sensory experiences, during the first hour after treatment. Patients will be monitored for these effects every five minutes for one hour after receiving the medication.

In addition to monitoring for psychodysleptic effects, the study will also assess how well each medication relieves pain and whether additional pain relief is needed. The intensity of any unusual effects and other possible side effects will be recorded every 15 minutes during the first hour of treatment. This study aims to provide valuable information on the effectiveness and side effects of low-dose ketamine and esketamine for managing severe acute pain.

Participants in the study will be randomly assigned to receive either Suboxone or methadone. The study will last for several months, during which participants will be monitored to see how their opioid use changes over time. They will be asked to complete questionnaires and may undergo various tests to assess their progress. The study aims to provide valuable information on which treatment might be more beneficial for people dealing with both opioid dependency and chronic pain.

Throughout the study, participants will be supported by healthcare professionals to ensure their safety and well-being. The results of this trial could help improve treatment options for individuals struggling with opioid use disorder and chronic pain, offering insights into the best ways to manage these conditions together.

The purpose of the study is to determine if the combination of ibuprofen (arginine) and tramadol hydrochloride provides better pain relief than the individual medications or a placebo. Participants in the study will receive the treatment every six hours for a short period after their dental surgery. The study will monitor how well the treatment reduces pain over the first 12 hours and up to 48 hours after starting the medication. Participants will also be observed for any side effects or adverse reactions to the treatment.

Throughout the study, participants will be asked to rate their pain using a simple scale, and researchers will track the need for any additional pain relief medication. The study aims to provide valuable information on the potential benefits of using this combination of medications for managing post-surgical pain, which could lead to improved pain management strategies for patients undergoing similar procedures in the future.

Participants in the study will receive the treatment after undergoing surgery, which may include procedures like myomectomy, hysterectomy, or cholecystectomy. The study will monitor how well the treatment controls pain over a period of several hours. The goal is to see if the combination of ibuprofen and tramadol can manage pain effectively and safely, providing relief without causing significant side effects.

Throughout the study, participants will be closely observed to assess their pain levels and any potential side effects. The study will compare the pain relief provided by the combination treatment to that of tramadol alone and a placebo, ensuring a comprehensive evaluation of its effectiveness. This research is important for developing better pain management strategies for patients recovering from surgery.

The purpose of the study is to determine if taking duloxetine around the time of surgery can lower the chances of experiencing long-term pain four months after the operation. The study will involve patients who are considered at high risk for developing chronic pain after their hernia repair. These patients will be monitored over a period to assess the incidence of chronic pain and any changes in their quality of life, as well as to record any side effects that may occur during the study.

Participants will be randomly assigned to receive either duloxetine or a placebo, and they will take the medication orally in the form of capsules. The study will track their progress and gather data on their pain levels and overall well-being. The findings from this trial could provide valuable insights into managing chronic pain after surgery and potentially improve recovery outcomes for patients undergoing inguinal hernia repair.

The purpose of the study is to evaluate how safe and tolerable this treatment is for children, as well as how effective it is at reducing pain. Children participating in the study will receive the nasal spray, and their pain levels will be monitored over a short period. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects. The study aims to see how quickly and effectively the treatment can reduce pain in an emergency care setting.

Throughout the study, researchers will observe changes in pain intensity at various time points after administering the treatment. This will help determine how well the nasal spray works in providing relief. The study is designed to ensure the safety of the participants while gathering valuable information about the potential benefits of this new treatment for managing pain in children.

Participants in the study will be divided into two groups. One group will receive the AP707 treatment, while the other group will receive a placebo, which looks and smells like the real treatment but does not contain the active ingredient. The study will last for about a year, during which participants will have regular check-ups to monitor their pain levels and overall health. The goal is to determine if AP707 can effectively reduce pain and improve the quality of life for those suffering from chronic pain due to nerve damage.

Throughout the study, participants will continue to use their regular pain medications, which may include drugs like Gabapentin, Capsaicin, Imipramine, Amitriptyline, and Paracetamol. These medications are commonly used to manage pain and will be optimized for each participant. The study will also assess any changes in psychological well-being, sleep quality, and overall life satisfaction. By the end of the study, researchers hope to gather valuable information on the potential benefits of AP707 for managing chronic pain.

Participants in the study will receive either the AP707 treatment or a placebo, which looks like the treatment but does not contain the active ingredient. The study will last for a total of 52 weeks, during which participants will be monitored at various intervals to assess changes in their pain levels and overall well-being. The treatment is administered as a sublingual spray, meaning it is sprayed under the tongue for absorption.

Throughout the study, participants’ pain levels will be measured using a simple scale, and other aspects such as quality of life, sleep quality, and psychological well-being will also be evaluated. The goal is to see if AP707 can provide significant relief from chronic pain and improve the quality of life for those affected by central neuropathy.

Participants in the study will receive either the AP707 treatment or a placebo, which looks like the treatment but does not contain the active ingredient. The study will be conducted over several weeks, with regular assessments to monitor changes in pain levels and overall well-being. The goal is to determine if AP707 can provide significant relief from pain compared to the placebo.

Throughout the trial, participants will be asked to report their pain levels and any changes in their condition. The study will also track any side effects or adverse events to ensure the safety of the treatment. By the end of the study, researchers hope to gather valuable information about the potential benefits of AP707 for those suffering from chronic pain due to diabetic polyneuropathy.

The purpose of the study is to evaluate how effective ODM-111 is in managing pain associated with diabetic peripheral neuropathy. Participants in the study will receive either ODM-111 or a placebo, and their pain levels will be monitored over a period of six weeks. The medication is taken orally in the form of tablets. Throughout the study, participants will be asked to record their daily pain levels using a simple numerical scale to help researchers assess any changes in pain intensity.

In addition to ODM-111, the study will also involve the use of Para-Tabs, which contain paracetamol, a common pain reliever. The study aims to provide valuable information on the potential benefits of ODM-111 for individuals suffering from chronic pain due to diabetic peripheral neuropathy, with the hope of improving treatment options for this condition.